This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?
by Sundeep Ganoria
Not your typical cannabis play. Discover why Jazz Pharma's FDA-approved CBD drug could make it a top cannabis stock to watch in 2025.
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
by Zacks Equity Research
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.
Ironwood Shares Tank on Regulatory Update for Apraglutide
by Zacks Equity Research
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
by Zacks Equity Research
The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
by Zacks Equity Research
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
by Zacks Equity Research
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up
by Zacks Equity Research
Tempest aims to explore strategic alternatives for advancing pipeline studies that maximize shareholder value. Stock rises in after-hours trading.
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?
by Zacks Equity Research
Jazz (JAZZ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHSC
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
by Zacks Equity Research
The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.
5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath
by Supriyo Bose
ANET, GLW, JAZZ, AES and PPC are some of the stocks with high ROE to profit from as markets recoiled on tariff war.
Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JHSC
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
by Zacks Equity Research
The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
by Zacks Equity Research
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
by Zacks Equity Research
Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680
by Zacks Equity Research
ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
by Zacks Equity Research
Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
by Zacks Equity Research
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.